Stephan Jackman
Chief Executive Officer at ALZAMEND NEURO, INC.
Net worth: 3 033 $ as of 2024-03-30
Profile
Stephan Jackman is currently the Chief Executive Officer & Director at Alzamend Neuro, Inc. He previously served as the Chief Operating Officer at Ennaid Therapeutics LLC from 2015 to 2017 and at Exit 9 Technologies, Inc. from 2017 to 2018.
Mr. Jackman received his undergraduate and graduate degrees from Stevens Institute of Technology.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
ALZAMEND NEURO, INC.
0.04% | 2023-08-23 | 3,033 ( 0.04% ) | 3 033 $ | 2024-03-30 |
Stephan Jackman active positions
Companies | Position | Start |
---|---|---|
ALZAMEND NEURO, INC. | Chief Executive Officer | 2018-11-19 |
Former positions of Stephan Jackman
Companies | Position | End |
---|---|---|
Exit 9 Technologies, Inc. | Chief Operating Officer | 2018-10-31 |
Ennaid Therapeutics LLC
Ennaid Therapeutics LLC BiotechnologyHealth Technology Ennaid Therapeutics LLC develops orally deliverable anti-viral peptide that treats and prevents Zika virus. The company was founded by Darnisha Grant Harrison in 2012 and is headquartered in Alpharetta, GA. | Chief Operating Officer | 2017-09-30 |
Training of Stephan Jackman
Stevens Institute of Technology | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
Alzamend Neuro, Inc. | |
Ennaid Therapeutics LLC
Ennaid Therapeutics LLC BiotechnologyHealth Technology Ennaid Therapeutics LLC develops orally deliverable anti-viral peptide that treats and prevents Zika virus. The company was founded by Darnisha Grant Harrison in 2012 and is headquartered in Alpharetta, GA. | Health Technology |
Exit 9 Technologies, Inc. |
- Stock Market
- Insiders
- Stephan Jackman